Nimrod Bar Zvi joined Pluri as chief commercial officer in 2022 to lead global commercialization of the company’s cell-based technology Platform. Mr. Bar Zvi brings extensive senior leadership experience in the global pharmaceutical markets and active ingredients, with over 15 years in executives roles building B2B strategies, CDMO, API & Pharma sales. Prior to joining Pluri, Nimrod was the CEO of a UK CDMO inhalation company, Pharmaserve NW and led the transformation to new green propellants in devices used to deliver respiratory drugs. Previously, Mr. Bar Zvi held various supply chain and commercial executive roles for Teva Pharmaceuticals and was responsible for developing Teva API growth strategy and entering new markets and businesses worldwide. Prior to that he served as Head of their North America, LATAM and China API commercial offices responsible for over 300m$ annual sales operations globally. Previously, he led Teva API Commercial operations in Europe and execution of strategic acquisitions for the region including establishment of new offices in Russia and prior to that he managed new established sales forces for Teva International Group in the Far-East markets with representation in over 15 Countries including first offices in China Mainland.

©2023 Pluri Inc.

©2023 Pluri Inc., its logo, brand, product, and process names appearing in this issue are the trademarks of Pluri™ Inc. or its affiliated companies. All other brand, product, and process names appearing are the trademarks of their respective holders. Reference to or use of a product, or process other than those of Pluri™ Inc. does not imply recommendation, approval, affiliation, or sponsorship of that product, or process by Pluri™ Inc. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent, copyright, trademark, or other intellectual property right of Pluri™ Inc. or any third party, except as expressly granted herein.  All information herein is for general information only and is subject for change without notice.

NAME

Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.